Publications by authors named "N Ariyoshi"
Article Synopsis
- A comparison of adverse events (AEs) between nivolumab plus ipilimumab (NIVO-IPI) and nivolumab plus cabozantinib (NIVO-CABO) was conducted using data from the FDA and WHO databases, as there were no direct clinical trials available.
- The analysis revealed that immune-related AEs, such as myocarditis and colitis, occurred more frequently with NIVO-IPI, whereas gastrointestinal and skin disorders were more common with NIVO-CABO.
- The results help inform treatment decisions to better manage and reduce the risk of AEs in patients with metastatic renal cell carcinoma (mRCC).
Introduction: Post-vitrectomy cystoid macular edema (CME) can lead to failure of macular hole (MH) closure. We report 2 cases of failure of MH closure due to post-vitrectomy CME, which were successfully treated using sub-Tenon triamcinolone acetonide (STTA) injection.
Case Presentations: Case 1 involved a 72-year-old male patient with a Gass Stage 3 MH in the right eye.
Introduction: Hypoxia-inducible factor-prolyl hydroxylase (HIF-PH) inhibitors, used in the treatment of renal anemia, hold the potential to increase the production of vascular endothelial growth factors. Therefore, HIF-PH inhibitors may exacerbate retinal hemorrhage in diseases such as diabetic retinopathy. Here, we present a case involving the administration of an HIF-PH inhibitor, resulting in the exacerbation of retinal hemorrhage in a patient with diabetic retinopathy.
View Article and Find Full Text PDFThe potential risks associated with organs from COVID-19-infected donors were unclear. To determine the SARS-CoV-2 infection status of corneas transplanted during the COVID-19 pandemic, we performed a polymerase chain reaction (PCR) using the corneal preservation solution that was used for corneal transplantation. We also examined the postoperative health status of the recipients.
View Article and Find Full Text PDFArticle Synopsis
- - This study compares the adverse event (AE) profiles of two breast cancer drugs, palbociclib and abemaciclib, using data from global databases to identify any differences in side effects.
- - It found that patients on palbociclib often reported cytopenia and psychiatric disorders, while those on abemaciclib reported more interstitial lung disease and diarrhoea, among other issues.
- - The results emphasize the need for healthcare providers to consider these differing side effects when prescribing CDK4/6 inhibitors for breast cancer treatment.